Articles tagged with Lymphoma
Preet Chaudhary and Michael Selsted, USC innovators, recognized by the National Academy of Inventors for their work on harnessing the power of the immune system. Their research aims to develop new treatments for diseases such as cancer, rheumatoid arthritis, and sepsis.
New leukemia treatment combination shows promise for patients with follicular lymphoma. Immunotherapy research also explores ways to suppress protein ZNF638 to boost effectiveness of immune checkpoint inhibitors. Innovative funding efforts support Sylvester's cancer research initiatives.
Dr. Owen Witte has been awarded the 12th annual Harrington Prize for Innovation in Medicine for his groundbreaking work on leukemia, lymphoma, and other cancers. His discoveries have led to life-saving therapies like Gleevec and ibrutinib, transforming cancer treatment.
Researchers from the University of Southern Denmark found that tattooed individuals are more frequently diagnosed with skin and lymphoma cancers compared to those without tattoos. The study suggests that chronic inflammation in the lymph nodes triggered by tattoo ink may lead to abnormal cell growth and an increased risk of cancer.
The new guidelines aim to reduce trauma and delays in cancer diagnosis and treatment during pregnancy. Led by Dr Georgia Mills and Dr Gisele Kidson-Gerber, the guidelines provide a practical guide for doctors, including recommendations for diagnosis, staging, imaging safety, therapy, and supportive care.
Researchers identified YTHDF2 as a key player in advancing blood cancers, which can help cancer cells evade immune system detection. A new compound CCI-38 targets and suppresses YTHDF2, reducing aggressive blood cancer growth.
Sylvester Comprehensive Cancer Center offers expert advice on coping with holiday loss and grief. Biological age can predict early colorectal cancer risk, while research advances may lead to a cure for multiple myeloma. Blood cancer experts share insights into new treatments.
Researchers found that a new chemotherapy regimen, eBEACOPDac, resulted in fewer and less severe side effects compared to the existing regimen, eBEACOPP. Patients treated with eBEACOPDac experienced improved fertility recovery and reduced hospital time, making it a potential game-changer for treating Hodgkin lymphoma.
A phase 3 trial shows that autologous stem cell transplants do not improve survival for mantle cell lymphoma patients in complete remission and undetectable minimal residual disease. Patients who remain MRD-positive after induction may benefit from ASCT, but longer follow-up is needed to confirm these findings.
Two clinical trials testing loncastuximab tesirine showed promising results in patients with high-risk forms of follicular lymphoma and marginal zone lymphoma. The treatment achieved impressive response rates, including a 70% complete response rate for marginal zone lymphoma and an overall response rate of 97% for follicular lymphoma.
A new study from Reichman University explores the impact of conflicting assessments on the FDA's role in regulating breast implants. The agency faces challenges in balancing the interests of the medical industry and public health, leading to underreporting and inconsistent enforcement of regulations.
A comprehensive epigenetic database of over 200 malignant cell lines has been developed, offering valuable insights into leukemia and lymphoma. The database allows researchers to predict drug sensitivity based on epigenetic lesions, aiding in tumour diagnosis and treatment.
Continuous Medicaid enrollment is associated with a lower rate of late-stage lymphoma diagnosis, but fewer than half of patients are continuously enrolled before diagnosis. The study found that continuous coverage was strongly linked to a lower likelihood of late-stage diagnosis, especially in young adults.
Researchers created tiny lab-grown models of human immune systems to study immune function in cancer and predict disease treatment response. The miniature models support longer cell function, allowing processes like antibody formation to occur similar to the human body.
The ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present several abstracts at the 66th American Society of Hematology Meeting & Exposition. Promising results from a phase 2 study in acute myeloid leukemia and new data from the practice-changing E1910 phase 3 trial show improved outcomes for patients with B-cell acute lymphobla...
A new treatment approach using immunotherapy has shown promising results in treating advanced Hodgkin lymphoma, with a remarkable 92% survival rate. The innovative clinical trial, led by Wilmot Director Jonathan Friedberg, also minimizes long-term side effects and toxicities.
The two-year progression-free survival rate was 92% on the N-AVD arm compared to 83% on the BV-AVD arm, with fewer side effects and lower mortality rates. The study's results support the use of nivolumab-AVD as a standard treatment for stage 3-4 classic Hodgkin lymphoma.
The RESILIENCE clinical trial explores the effectiveness of remote ischemic conditioning to prevent cardiotoxicity in lymphoma patients undergoing anthracycline-based chemotherapy. The trial aims to reduce heart failure prevalence and improve quality of life for cancer survivors.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Researchers found that type II innate lymphoid cells transform after a cancer patient receives stem cells from a donor, preventing an effective immune system rebuilding. This new understanding may lead to better strategies for enhancing immune system recovery post-transplantation.
Patients with mantle cell lymphoma are more vulnerable to other diseases and infections due to intensive chemotherapy and a weakened immune system. A large-scale national study found that MCL patients had twice as many infections as reference subjects, with common causes including influenza and urinary tract infections.
Patients with CLL and NHL who received frequent immunoglobulin G tests had fewer infections, required fewer antimicrobial medications, and higher blood levels of IgG. Increased IgG testing is associated with a lower risk of severe infections, suggesting that clear clinician guidance may save lives.
Dr Biola M Javierre has been awarded a prestigious grant to study the role of mutations in noncoding regions of the genome in diffuse large B-cell lymphoma (DLBCL). Her research aims to identify genes affected by these mutations and their potential therapeutic targets.
Researchers at Wyss Institute develop subcutaneous scaffolds to restimulate CAR-T cells, increasing therapeutic efficacy in mice with aggressive blood tumors. The biomaterials increase CAR-T cell numbers and steer differentiation into tumor-killing T cells.
Researchers at UC Davis have updated their guidelines on neutering popular dog breeds, finding major differences in joint disorders and cancers. The study emphasizes personalized decisions, considering breed, sex, and context, and provides a table with guidelines for all 40 studied breeds.
A recent study from Lund University suggests that tattoos may be a risk factor for cancer in the lymphatic system. Researchers found that individuals with tattoos had a 21% higher risk of developing lymphoma compared to those without tattoos.
Fred Hutch researchers present progress in treating metastatic cancer with novel therapies, including a Phase II study testing TNF-a inhibitors for castration-resistant prostate cancer. The center also explores improving hospice access and using machine learning with CAR T-cell therapy to enhance patient outcomes.
Researchers at Weill Cornell Medicine have identified mutations in the ARID1A gene that drive follicular lymphoma transformation into a more aggressive form. These mutations make patients highly susceptible to experimental BAF-inhibitor drugs, offering new hope for early intervention therapies.
A new AI model, called Lars, can accurately detect signs of lymph node cancer in 90% of cases, reducing workload for radiologists and increasing access to healthcare. The model was developed using a large dataset of over 17,000 images from 5,000 patients and is based on deep learning technology.
A recent study published in the Journal of Veterinary Medicine found no significant correlation between canine lymphoma and proximity to environmental toxins. Researchers used data from Morris Animal Foundation's Golden Retriever Lifetime Study to map dog home addresses to radon zones and fracking wells, but did not find a link.
Sezáry syndrome patients face a vicious circle where cancer and treatment weaken the immune system, allowing bacteria like S. aureus to thrive. Eliminating these bacteria may make cancer cells more susceptible to anti-cancer drugs.
Researchers from Brazil discuss the management of refractory or relapsed classic Hodgkin lymphoma in adults, highlighting novel agents such as brentuximab vedotin and immunotherapy. The Brazilian healthcare system's constraints are also considered when making treatment decisions.
A new study has identified protein expression patterns that can predict the progression of follicular lymphoma, an incurable type of cancer. By analyzing tumour samples from patients, researchers have found a correlation between specific proteins and disease transformation, enabling early detection of high-risk patients.
A Stanford Medicine-led study identified circulating tumor DNA as a predictor of disease recurrence and grouped Hodgkin lymphoma into two subgroups with distinct genetic changes. This discovery may lead to more effective treatments with reduced toxicity.
A phase 2 trial PrE0405 showed an 85% complete response rate in 33 patients over 60 with mantle cell lymphoma who received venetoclax combined with bendamustine and rituximab. The combination was generally well-tolerated, with gastrointestinal toxicities common.
Researchers have identified a common mutation in the transcription factor IRF4 that drives tumor cell development in Hodgkin's lymphoma. This mutation leads to the activation of disease-relevant genes, and blocking its effects could provide new therapeutic opportunities.
Men who are overweight or obese at age 18 have a higher risk of developing 17 different cancers later in life. Higher BMI is also associated with an increased risk of mortality after cancer diagnosis for certain types of cancer.
A recent study by UTHealth Houston found that the offspring of adolescent and young adult women with a history of cancer face a higher risk of birth defects. The study examined 6,882 offspring ages 12 months and younger and found an increased risk of specific types of defects in the offspring of women with a history of cancer.
Researchers found a 55% reduction in lymphoma risk and a 40% overall reduction in blood cancer risk among bariatric surgery patients. Women with high blood sugar at the start of the study benefited most from the surgery.
Dr. Hung Nguyen is studying how medium chain fatty acid foods like coconut oil and avocados affect GVHD severity and mortality in transplant patients. His goal is to develop a dietary approach that reduces inflammation and corticosteroid use, improving patient outcomes for blood cancers.
A multicenter team has identified three risk biomarkers for chronic graft-versus-host-disease, which can be measured at 90 days after transplantation. These markers include MMP3, DKK3, and CXCL9, which are associated with fibrosis, inflammation, and immune cell attraction.
Research by the University of Southampton found that repeated COVID-19 vaccine doses increase immune response in blood cancer patients, generating higher-quality antibodies. Booster vaccinations are essential for maintaining protection against COVID-19 in immunocompromised individuals.
Research found that women treated for childhood Hodgkin lymphoma may experience declining fertility and longer wait times to become pregnant, but overall success rates are high. The majority of women in the study who had tried to become pregnant were successful, with some being able to conceive at a younger age.
Researchers have created a new prediction tool to evaluate the benefits of blood cancer treatments, filling a gap in previous versions. The ESMO-MCBS:H v1.0 tool uses a validated algorithm to assess clinical benefits, survival data, and quality of life, providing a transparent assessment for clinicians.
Researchers have identified LP-284 as a novel acylfulvene compound with anti-tumor activity against non-Hodgkin's lymphoma. The compound exerts nanomolar potency in 15 NHL cell lines and prolongs survival of mantle cell lymphoma xenograft mice, making it a potential therapeutic option for patients with HR or TC-NER deficiency.
Researchers analyzed 23 pregnant women with relapsed/refractory lymphoma and found a 24% progression-free survival rate and an 83% overall survival rate. The study suggests that delays in treatment may allow cancer to progress, while initiating chemotherapy can harm the fetus.
A new Northwestern Medicine study found young adult cancer survivors (18-39 years old) are 2.6 times more likely to develop heart failure when treated with anthracyclines. The incidence is highest among leukemia and other specific cancer types.
A study of 7807 children found no increased risk of brain tumours, leukemia, or lymphoma after a single CT scan. However, exposure to 4 or more scans before adulthood significantly increases the risk of intracranial tumours, leukemia, and non-Hodgkin lymphoma
Researchers at Moffitt Cancer Center have identified a critical pathway in the development of MYC-driven lymphoma, involving the chemical modification of eIF5A with hypusine. Inhibiting this process prevents lymphoma development and progression in mouse models, offering new therapeutic strategies.
Researchers at Georgia Institute of Technology developed a synthetic tumor model to understand the impact of microenvironment on targeted therapies for Activated B Cell-like Diffuse Large B cell lymphoma. The model showed promise in demonstrating how combining therapeutics can overcome tumor resistance to inhibitors.
Researchers have found a new solution to combat resistant staphylococcus aureus infections, which can be difficult to treat. Endolysins, a newly developed enzyme, has been shown to kill both resistant and non-resistant staphylococcus aureus without the need for antibiotics.
A new study using whole genome sequencing identifies previously unknown mutations driving Hodgkin lymphoma development. The research provides temporal insights into tumor evolution, enabling more precise targeted treatment options.
Researchers have found that blood cancer tumours use signals to attract certain types of immune cells and instruct them not to attack. High concentrations of these cell clusters predict treatment failure, but a different microenvironment is associated with treatment success.
A new study found that the antibody-drug conjugate STRO-001 showed nanomolar cytotoxicity in 88% of cancer cell lines tested, with potent efficacy against proliferating B cells. The research supports ongoing clinical studies for patients with B-cell non-Hodgkin lymphoma.
Researchers at Australian National University and Peter MacCallum Cancer Centre found that targeting the Menin protein can reactivate dormant genes, making cancer cells visible to the immune system. This discovery could lead to more effective treatments for lymphoma and lung cancer by combining Menin inhibitors with existing therapies.
Researchers describe results using cladribine-based combination epigenetic and immunotherapy in MCL, achieving an increased overall survival greater than 40 months with durable remissions without relapse for longer than 5 years. The approach is promising in the treatment of MCL and potentially other previously treatment-refractory canc...
A new Columbia University study has found that breast implants after mastectomy are associated with an extremely low risk of developing a rare cancer called anaplastic large-cell lymphoma (ALCL). According to the study, only five cases of ALCL were diagnosed among 57,000 women who had undergone reconstructive surgery over 421,000 years...
A systematic review of national clinical practice guidelines in Europe found that fewer than half include HIV testing recommendations for patients with medical conditions indicating HIV infection. This omission hinders efforts to stop the spread of HIV through timely diagnosis, affecting the lives of people living with HIV.
Researchers at Weill Cornell Medicine found a new way to target mantle cell lymphoma by inhibiting the activity of FOXO1 protein, which coordinates gene expression. The discovery could lead to new treatments and improved understanding of how this type of lymphoma develops.
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.